RBS Australia rates ACR as Buy 25 August 2010 FN Arena
Acrux has just delivered its first ever profit and RBS analysts warn investors: there's more of the same to come in the periods ahead. The company is expected to start paying out dividends from the present fiscal year onwards. It's but two more steps in a long queue of milestones reached by the company in recent times.
This year should see strong profit growth and RBS lines up several more milestones that should be forthcoming. Bottom line: that Buy rating remains in place. Price target has fallen slightly to $3.13 from $3.17.
Sector: Pharmaceuticals, Biotechnology and Life Sciences.Target price is $3.13.Current Price is $2.00. Difference: $1.13 - (brackets indicate current price is over target). If ACR meets the RBS Australia target it will return approximately 36% (excluding dividends, fees and charges - negative figures indicate an expected loss).
ACR Price at posting:
$2.08 Sentiment: Buy Disclosure: Held
